Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of cisplatin and etoposide in treating patients with CNS tumors.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: National Cancer Institute (NCI)
• Treatments: Cisplatin; Etoposide; Etoposide phosphate

Criteria

DISEASE CHARACTERISTICS:

• Histologically proven CNS germ cell tumor of 1 of the following subtypes:

• CNS germinoma

• Immature teratoma

• Embryonal cell carcinoma

• Yolk sac tumor

• Endodermal sinus tumor

• Choriocarcinoma OR

• Pineal or suprasellar mass associated with elevated CSF alpha fetoprotein or beta-human chorionic gonadotropin allowed

• Patients 18 years and over with localized pure germinomas ineligible

• Evaluable CT or MRI of brain and/or spinal cord required

PATIENT CHARACTERISTICS:

Age:

• 3 and over

Hematopoietic:

• Age 18 and over:

• WBC at least 4,000/mm^3

• Platelet count at least 100,000/mm^3

• Under age 18:

• Absolute neutrophil count at least 1,000/mm^3

• Platelet count at least 100,000/mm^3

Hepatic:

• Not specified

Renal:

• Creatinine no greater than 0.3 mg/dL above upper limit of normal for age

Other:

• No uncontrolled infection

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• No prior chemotherapy for CNS germ cell tumor

Endocrine therapy:

• Concurrent corticosteroids allowed except as antiemetics

Radiotherapy:

• No prior cranial or spinal radiotherapy

Surgery:

• Not specified